Skip to content

Author

Takashi Kijima

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Treatment-specific Association of H&E-based Stromal Tumor-infiltrating Lymphocytes With Survival in Pleural Mesothelioma Treated With Ipilimumab/Nivolumab or Chemotherapy

Background/Aim: Pleural mesothelioma lacks robust biomarkers to guide personalized treatment selection. Although stromal tumor-infiltrating lymphocytes (sTILs) on hematoxylin and eosin (H&E)-stained sections represent a cost-effective biomarker in various cancers, their clinical significance in pleural mesothelioma rem...

Takashi Yamasaki, Koji Yamanegi, H. Ota et al. · 0 citations
Open access Jul 2026

Osimertinib vs. erlotinib combined with an angiogenesis inhibitor in EGFR-mutated non-small cell lung cancer with malignant pleural effusion: a retrospective cohort study

Background Osimertinib is the standard first-line treatment for non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. Erlotinib plus an angiogenesis inhibitor (erlotinib+A) has demonstrated efficacy in controlling malignant pleural effusion (MPE) through reduction of vascular...

T. Hata, T. Yamada, Koji Mikami et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.